Quantum BioPharma Ltd. (QNTM) Key Metrics
QNTM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $15.9M
- Enterprise value
- $28.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 91.9
- Price / book
- 3.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.38
QNTM key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsQNTM returns How much profit the business earns on the capital it uses.
QNTM financial health Debt, liquidity and how easily interest is covered.
QNTM efficiency & capital use Working capital cycle and where the cash goes.
QNTM valuation history
QNTM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
QNTM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
QNTM cash returned to shareholders
QNTM price vs earnings per share
QNTM key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $24.0M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $19.7M | — | — | — | — | — | — | — | — | — |
| Price / book | 3.5 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −109.1% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −34.9% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.30 | $3.68 | $59.80 | $51.22 | $66.30 | $101.40 | $2,795.91 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$7.97 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.55 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.55 | — | — | — | — | — | — | — | — | — |
| Cash per share | $1.88 | — | — | — | — | — | — | — | — | — |
| Book value per share | $2.10 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.73 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.57 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 3.3M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −284.6% | −114.9% | −81.8% | −55.8% | −78.0% | −87.6% | −95.6% | −57.1% | — | — |
| Return on invested capital (ROIC) | −313.1% | −168.1% | −155.8% | −130.1% | −138.3% | −125.7% | — | −73.3% | — | — |
| Return on assets (ROA) | −185.2% | −82.1% | −64.1% | −46.6% | −67.3% | −75.8% | −91.2% | −51.5% | −637.4% | — |
| Return on tangible assets | −394.5% | −116.6% | −147.7% | −89.5% | −75.5% | −111.4% | −58.4% | −25.8% | −415.1% | — |
| Financial health | ||||||||||
| Total debt | $1.9M | $824,922 | $339,199 | $516,423 | $555,905 | $510,609 | — | — | — | $18,035 |
| Cash & short-term investments | $6.2M | $7.2M | $3.5M | $17.0M | $35.4M | $17.5M | $15.5M | $3.8M | $7,137 | — |
| Net debt | −$4.3M | −$6.4M | −$3.2M | −$16.5M | −$34.9M | −$17.0M | −$15.5M | −$3.8M | −$7,137 | $18,035 |
| Debt / equity | 0.27 | 0.07 | 0.03 | 0.02 | 0.01 | 0.01 | — | — | — | — |
| Debt / assets | 0.17 | 0.05 | 0.02 | 0.01 | 0.01 | 0.01 | — | — | — | 8.35 |
| Current ratio | 1.07 | 1.80 | 2.43 | 2.28 | 5.28 | 4.82 | 12.94 | 4.26 | 0.12 | 0.04 |
| Quick ratio | 1.06 | 1.79 | 2.43 | 2.28 | 5.28 | 4.82 | 12.94 | 4.26 | 0.12 | 0.04 |
| Interest coverage | -24.7 | -339.2 | — | -561.8 | -486.2 | -130.3 | — | — | — | — |
| Working capital | $419,295 | $5.4M | $6.5M | $10.0M | $37.2M | $21.3M | $15.3M | $3.3M | −$54,297 | −$58,370 |
| Invested capital | $2.6M | $5.1M | $10.1M | $14.1M | $19.3M | $19.3M | $22.0M | $6.1M | −$61,434 | −$40,335 |
| Tangible asset value | $588,336 | $5.5M | $7.6M | $18.5M | $37.9M | $22.9M | $37.5M | $9.9M | −$54,297 | −$58,370 |
| Net current asset value | $419,295 | $5.4M | $6.5M | $10.0M | $37.1M | $21.2M | $15.3M | $3.3M | −$54,297 | −$58,370 |
| Graham net-net per share | $0.10 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $0 | $0 | $3.0M | $1.9M | $0 | $0 | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | — | 29,502.0% | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.08 | 0.12 | 0.00 | 22.08 | — | — | — |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | 11,527.9% | — | — |
| SG&A / revenue | — | — | — | — | — | — | — | 13,686.0% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | 4,143.6 | — | — |
| Days of inventory on hand | 55.6 | 43.6 | — | — | — | — | — | — | — | — |
| Days payables outstanding | 1,720.9 | 2,416.4 | — | — | — | — | 2,285.7 | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | — | 0.00 |
| Payables turnover | 0.21 | 0.15 | — | — | — | — | 0.16 | 0.00 | — | — |
| Inventory turnover | 6.56 | 8.37 | — | — | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $2.0M | $5.6M | $3.9M | $437,670 | $331,153 | $161,342 | $606,874 | $234,201 | — | $2,160 |
| Average payables | $2.6M | $3.2M | $3.0M | $2.9M | $2.5M | $2.1M | $1.1M | $517,532 | $32,531 | $36,753 |
| Average inventory | $84,640 | $58,621 | $0 | — | — | $0 | — | — | — | — |
| Intangibles / total assets | 40.4% | 28.8% | 30.6% | 31.3% | 25.7% | 32.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from QNTM's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
QNTM valuation and financial ratios
Quantum BioPharma earned a return on equity of −284.6% and a return on invested capital of −313.1% in fiscal 2025. It ended the year with $1.9 million of debt and $6.2 million in cash and short-term investments, a net cash position of $4.3 million.
See the QNTM income statement, the QNTM chart for price history, or the QNTM stock overview for the latest quote and news.
QNTM key metrics FAQ
What is Quantum BioPharma's return on equity?
Quantum BioPharma's return on equity (ROE) was −284.6% in fiscal 2025: net income of -$26.2 million on average shareholders' equity of $9.2 million.
What is Quantum BioPharma's ROIC?
Quantum BioPharma's return on invested capital was −313.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Quantum BioPharma have?
Quantum BioPharma had total debt of $1.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.27 and more cash than debt.
What is Quantum BioPharma's free cash flow yield?
Quantum BioPharma generated -$8.4 million of free cash flow in fiscal 2025, a free cash flow yield of −34.9% on its market value at year-end ($24.0 million).
What is Quantum BioPharma's current ratio?
Quantum BioPharma's current ratio was 1.07 at the end of fiscal 2025: current assets were 1.07 times current liabilities.